Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Zolbetuximab treatment in metastatic gastric cancer706
Hybrid EASL Congress 2023668
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology646
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis574
Mapping neuroimmune interactions in the gut564
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed509
2023 FDA approvals in gastroenterology and hepatology500
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa439
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection353
Western lifestyle, metaflammation and the cell of origin of colon cancer339
Advancing nutrition science for global health300
The future of treating pancreatic exocrine insufficiency298
Digestive Disease Week 2022286
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection272
Nomenclature of HBV core protein-targeting antivirals271
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis253
Artificial intelligence and automation in endoscopy and surgery243
Black–White disparities across the colorectal cancer care continuum in the USA242
Large language models for clinical decision support in gastroenterology and hepatology224
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health222
New understanding of hepatobiliary MRI218
Metastatic pancreatic cancer and the liver210
Lessons from incretin-based therapy in MASH and obesity198
Food as medicine in gastrointestinal cancer therapy191
Novel insights into chronic HBV infection191
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract187
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges181
A crucial Fusobacterium nucleatum clade in colorectal cancer174
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation172
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease171
The critical role of gut–brain signalling in eating behaviour and obesity170
Inflammatory bowel disease in pregnancy and breastfeeding164
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases160
Hepatocyte-derived biomarkers in alcohol-related cirrhosis158
Integrated systems approach to identify environmental factors in intestinal inflammation154
Characterizing the genomic landscape of colorectal cancer148
Implications of the evolving knowledge of the genetic architecture of MASLD146
Liver, ageing and disease142
Probiotics for preterms: sharing complex decision-making138
Estimating dietary intake from human stool DNA136
HDCA ameliorates NAFLD in mice129
Preventing the progression of cirrhosis to decompensation and death127
Medical therapy of paediatric inflammatory bowel disease123
SSRIs and depression: role of gut–brain communication117
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management110
The path to successful hepatitis C elimination in Spain109
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease101
Metabolic diseases in the East Asian populations99
Proteases in intestinal health and disease95
Human intestinal B cells in inflammatory diseases93
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook92
Phase III results for first-line treatment for metastatic colorectal cancer91
NAFLD prevalence in older patients with T2DM91
Microbiota and colorectal cancer — controlling for confounders challenges associations83
ECCO’2483
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’83
Enteric nervous system transfers stress to the gut82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance75
The future of pathology in gastroenterology and hepatology72
HIV-associated gut microbiome influences gut mucosal immunity71
Transforming the landscape of liver cancer detection and care70
Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?67
Author Correction: Hepatic immune regulation and sex disparities66
GLP1R agonists in NAFLD: a promising therapy on the horizon66
0.31502199172974